Impact of squamous histology on outcomes with enfortumab vedotin in patients with advanced urothelial carcinoma: Analysis of the UNITE study.

被引：0
|
作者：
Jindal, Tanya
Alhalabi, Omar
Nguyen, Charles B.
Bakaloudi, Dimitra Rafailia
Nizam, Amanda
Bilen, Mehmet Asim
Basu, Arnab
Zakharia, Yousef
Milowsky, Matthew I.
Brown, Jason R.
Kilari, Deepak
Shah, Sumit
Emamekhoo, Hamid
Grivas, Petros
Hoimes, Christopher J.
Gupta, Shilpa
Bellmunt, Joaquim
Campbell, Matthew T.
Alva, Ajjai Shivaram
Koshkin, Vadim S.
机构：
[1] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
[2] Univ Texas MD Anderson Canc Ctr Houston, Dept Genitourinary Med Oncol, Houston, TX USA
[3] Michigan Med, Ann Arbor, MI USA
[4] Univ Washington, Dept Med, Div Oncol, Seattle, WA USA
[5] Cleveland Clin, Cleveland, OH USA
[6] Emory Univ, Winship Canc Inst, Atlanta, GA USA
[7] Univ Alabama Birmingham, Birmingham, AL USA
[8] Univ Iowa, Holden Comprehens Canc Ctr, Iowa City, IA USA
[9] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA
[10] Univ Hosp Seidman Canc Ctr, Cleveland, OH USA
[11] Med Coll Wisconsin, Dept Med, Div Hematol & Oncol, Milwaukee, WI USA
[12] Stanford Canc Ctr, Stanford, CA USA
[13] Univ Wisconsin, Madison, WI USA
[14] Univ Washington, Div Hematol & Oncol, Seattle, WA USA
[15] Fred Hutchinson Canc Ctr, Seattle, WA USA
[16] Duke Univ, Duke Canc Inst, Durham, NC USA
[17] Cleveland Clin, Taussig Canc Inst, Cleveland, OH USA
[18] Dana Farber Canc Inst, Boston, MA USA
[19] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[20] Univ Michigan, Dept Internal Med, Div Hematol & Oncol, Ann Arbor, MI USA
[21] Univ Calif San Francisco, Dept Med, Div Hematol & Oncol, San Francisco, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
261-566-9263; 283-183-138-12099; 2; 3224; 3; 1;
D O I：
10.1200/JCO.2024.42.4_suppl.651
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：651 / 651
页数：1
相关论文
共 50 条
  • [1] Outcomes with enfortumab vedotin in patients with advanced urothelial carcinoma and histology variants: Analysis of the UNITE study.
    Jindy, Tanya
    Jiang, Cindy Y.
    Alhalabi, Omar
    Nguyen, Charles B.
    Nizam, Amanda
    Basu, Arnab
    Bilen, Mehmet Asim
    Zakharia, Yousef
    Milowsky, Matthew I.
    Brown, Jason R.
    Kilari, Deepak
    Emamekhoo, Hamid
    Hoimes, Christopher J.
    Khaki, Ali Raza
    Gupta, Shilpa
    Grivas, Petros
    Bellmunt, Joaquim
    Campbell, Matthew T.
    Alva, Ajjai Shivaram
    Koshkin, Vadim S.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 652 - 652
  • [2] Independent biomarkers predictive of outcomes with enfortumab vedotin (EV) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study.
    Jindal, Tanya
    Zhang, Li
    Jiang, Cindy
    Kilari, Deepak
    Alhalabi, Omar
    Nizam, Amanda
    Basu, Arnab
    Bilen, Mehmet Asim
    Zakharia, Yousef
    Milowsky, Matthew I.
    Shah, Sumit
    Hoimes, Christopher J.
    Davis, Nancy B.
    Gupta, Shilpa
    Emamekhoo, Hamid
    Grivas, Petros
    Bellmunt, Joaquim
    Campbell, Matthew T.
    Alva, Ajjai Shivaram
    Koshkin, Vadim S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] Biomarkers of response to enfortumab vedotin (EV) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study.
    Jindal, Tanya
    Kilari, Deepak
    Alhalabi, Omar
    Nizam, Amanda
    Khaki, Ali Raza
    Basu, Arnab
    Barata, Pedro C.
    Bilen, Mehmet Asim
    Shah, Sumit
    Zakharia, Yousef
    Milowsky, Matthew I.
    Bellmunt, Joaquim
    Emamekhoo, Hamid
    Davis, Nancy B.
    Grivas, Petros
    Gupta, Shilpa
    Hoimes, Christopher J.
    Campbell, Matthew T.
    Alva, Ajjai Shivaram
    Koshkin, Vadim S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [4] Outcomes in patients (pts) with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin (EV) after switch maintenance avelumab (MAv) in the UNITE study.
    Nizam, Amanda
    Jindal, Tanya
    Jiang, Cindy Y.
    Alhalabi, Omar
    Bakaloudi, Dimitra Rafailia
    Talukder, Rafee
    Davidsohn, Matthew P.
    Nguyen, Charles B.
    Oh, Eugene
    Taylor, Amy K.
    Lemke, Emily
    Kilari, Deepak
    Hoimes, Christopher J.
    Emamekhoo, Hamid
    Gupta, Shilpa
    Bellmunt, Joaquim
    Grivas, Petros
    Campbell, Matthew T.
    Alva, Ajjai Shivaram
    Koshkin, Vadim S.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 537 - 537
  • [5] Efficacy of enfortumab vedotin in advanced urothelial cancer: Retrospective analysis of the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) Study.
    Koshkin, Vadim S.
    Sun Yilun
    Freeman, Dory
    Osterman, Chelsea K.
    Su, Christopher
    Natesan, Divya
    Khaki, Ali Raza
    Makrakis, Dimitrios
    Jain, Jayanshu
    Olsen, Anders
    Basu, Arnab
    Barata, Pedro C.
    Zakharia, Yousef
    Bilen, Mehmet Asim
    Emamekhoo, Hamid
    Davis, Nancy B.
    Milowsky, Matthew, I
    Kilari, Deepak
    Sonpavde, Guru
    Alva, Ajjai Shivaram
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [6] Enfortumab Vedotin in Advanced Urothelial Carcinoma
    Petrylak, Daniel P.
    Powles, Thomas
    Rosenberg, Jonathan E.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (01): : 93 - 94
  • [7] Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab Vedotin
    Jindal, Tanya
    Zhang, Li
    Deshmukh, Prianka
    Reyes, Kevin
    Chan, Emily
    Kumar, Vipul
    Zhu, Xiaolin
    Maldonado, Edward
    Feng, Stephanie
    Johnson, Michelle
    Angelidakis, Austin
    Kwon, Daniel
    Desai, Arpita
    Borno, Hala T.
    Bose, Rohit
    Wong, Anthony
    Hong, Julian
    Carroll, Peter
    Meng, Maxwell
    Porten, Sima
    Aggarwal, Rahul
    Small, Eric J.
    Fong, Lawrence
    Chou, Jonathan
    Friedlander, Terence
    de Kouchkovsky, Ivan
    Koshkin, Vadim S.
    CLINICAL GENITOURINARY CANCER, 2023, 21 (05) : e394 - e404
  • [8] Biomarkers of response to sacituzumab govitecan (SG) and efficacy after treatment with enfortumab vedotin (EV) in advanced urothelial carcinoma (aUC): Analysis of the UNITE study.
    Jindal, Tanya
    Jiang, Cindy
    Alhalabi, Omar
    Bakaloudi, Dimitra Rafailia
    Talukder, Rafee
    Davidsohn, Matthew
    Nizam, Amanda
    Taylor, Amy K.
    Nguyen, Charles B.
    Kilari, Deepak
    Pywell, Cameron
    Davis, Nancy B.
    Emamekhoo, Hamid
    Sonpavde, Guru P.
    Gupta, Shilpa
    Bellmunt, Joaquim
    Grivas, Petros
    Campbell, Matthew T.
    Alva, Ajjai Shivaram
    Koshkin, Vadim S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [9] Clinical outcomes in patients with advanced urothelial carcinoma treated with enfortumab vedotin: A retrospective multicenter study in Japan
    Hara, Takuto
    Matsushita, Yuto
    Harada, Kenichi
    Fujimoto, Naohiro
    Fujisawa, Masato
    Miyake, Hideaki
    INTERNATIONAL JOURNAL OF UROLOGY, 2024, 31 (06) : 696 - 698
  • [10] Impact of Relative Dose Intensity of Enfortumab Vedotin for Advanced Urothelial Carcinoma
    Furubayashi, Nobuki
    Negishi, Takahito
    Mochida, Manabu
    Kijima, Atsuhiro
    Katsuki, Harumichi
    Nakamura, Motonobu
    IN VIVO, 2025, 39 (01): : 411 - 418
12345